| abstract |
A method of improving the efficacy of antibody associated cytotoxicity (ADCC) for the treatment associated with the killing of tumor cells is disclosed. Cancer specific cell surface antigens are bound by monoclonal antibodies, thereby stimulating cytotoxic T cell responses characterized by upregulation of cell surface expression of costimulatory molecules in T cells. ADCC responses are increased by sequential administration of secondary antibodies, which are agents of costimulatory molecules. |